This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

43/100

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Down syndrome and Alzheimer's

Topic: Amyloid, tau and blood-test diagnosis

Participant and visit numbers varied by measure, with 455 participants evaluated over 1178 data points. Models with PII group/slope differences were significant only for cognitive performance. Mild PII was associated with significantly later age of cognitive decline (55.2 years old vs 52.6 years old). PII influenced mCRT slope when separately examining free and cued recall scores, with mild PII's having a steeper free recall slope countered by a mild PII-specific nonmonotonic, initially increasing, cued slope. Slope differences by PII cancel out when summed in the CRT total. Differences in PII did not significantly affect amyloid, tau, or neurodegeneration biomarker trajectories. Cognitive decline timing and slope differ depending on PII level, but AD biomarker pathology does not. If cognition is used for staging or endpoints in clinical trials, then PII should be considered.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kennedy, J. T. (2025). Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_099392

Vancouver

Kennedy JT. Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_099392. PMID: 41442130.

BibTeX

@article{kennedy2025-41442130,
  author  = {Kennedy, James Tyler},
  title   = {{Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_099392},
  pmid    = {41442130},
  url     = {https://doi.org/10.1002/alz70856_099392}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Participant and visit numbers varied by measure, with 455 participants evaluated over 1178 data points.
Models with PII group/slope differences were significant only for cognitive performance.
Mild PII was associated with significantly later age of cognitive decline (55.2 years old vs 52.6 years old).
PII influenced mCRT slope when separately examining free and cued recall scores, with mild PII's having a steeper free recall slope countered by a mild PII-specific nonmonotonic, initially increasing, cued slope.
Slope differences by PII cancel out when summed in the CRT total.

Why it matters

In people with Down syndrome, having mild premorbid intellectual impairment was linked to a later age of cognitive decline, but it did not significantly affect amyloid, tau or neurodegeneration biomarker trajectories. The authors suggest that if cognition is used for staging or as an endpoint in clinical trials, premorbid intellectual impairment level should be considered.

Study details

Study designcross-sectional
Participants455
Evidence strengthModerate

How this study scored 43/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 41 of the 96 points we could judge it on, which is 43 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	455 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author James Tyler Kennedy holds only 6 work(s), too few to judge a track record — left out of this score
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41442130)
Free to read	2 / 2	Free to read
Points	41 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 96 points we could judge it on is 43 out of 100.
Total	43 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Down syndrome and Alzheimer's

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →